Press Release | Association for Accessible Medicines

Applauding Nomination of Dr. Scott Gottlieb to Lead the FDA

Oct 11, 2018 | Rachel Schwartz

AAM Statement on FDA Record Generic Approvals

New NAFTA - Proposed US-Mexico-Canada Agreement (USMCA)

Oct 1, 2018 | Rachel Schwartz

AAM Opposes Barriers to Generic Drug and Biosimilar Access in Proposed US-Mexico-Canada Agreement (USMCA)

Sep 24, 2018 | Rachel Schwartz

Dana Mariani Joins AAM as Director, Policy

Sep 20, 2018 | Rachel Schwartz

AAM Statement on CBO CREATES Score

Sep 4, 2018 | Rachel Schwartz

New Study Finds Patients, Government and Insurance Lose $13.4B in Potential Savings By Brand Drug Companies’ Abuses

New NAFTA - North American Generic Drugmakers Call for Rejection of New Exclusivity Period for Biologics

Aug 28, 2018 | Rachel Schwartz

North American Generic Drugmakers Call for Rejection of New Exclusivity Period for Biologics

FDA's Competitive Generic Therapy (CGT) Designation

Aug 8, 2018 | Rachel Schwartz

AAM Statement in Response to FDA's Competitive Generic Therapy (CGT) Designation

Jul 19, 2018 | Allen Goldberg

AAM Statement on Importation Task Force

AAM Statement on FDA’s Biosimilars Action - Press Release Header

Jul 18, 2018 | Allen Goldberg

AAM Statement on FDA’s Biosimilars Action Plan

Trump & HHS Blueprint to Lower Drug Prices (RFI)

Jul 16, 2018 | Allen Goldberg

AAM Provides Comments in Response to Administration’s Blueprint on Drug Pricing

2018 AAM Access and Savings in the U.S. Report

Jul 10, 2018 | Rachel Schwartz

Generic Drug Competition Lowers Prescription Cost to $6 on Average, Study Finds

Jun 26, 2018 | Rachel Schwartz

AAM Statement in Response to Secretary Azar’s Testimony Before Senate Finance Committee